Patent · US Active

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

US10400010B2 · kind B2 · utility

0Cited by

4References

30Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

David S. Eisenberg · Los Angeles, US
Alice Soragni · Los Angeles, US
Lin Jiang · Los Angeles, US

Key dates

Filing date	Jan 22, 2018
Grant date	Sep 3, 2019
Priority date	—
Expiry date	Jan 22, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.